These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8772621)

  • 1. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
    Carlsen SM; Rossvoll O; Bjerve KS; Følling I
    J Intern Med; 1996 Mar; 239(3):227-33. PubMed ID: 8772621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease.
    Carlsen SM; Grill V; Følling I
    Diabetes Res Clin Pract; 1998 Jan; 39(1):47-54. PubMed ID: 9597374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
    Akanji AO; Mojiminiyi OA; Abdella N
    Eur J Clin Nutr; 2000 Jun; 54(6):508-13. PubMed ID: 10878654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
    Ko GT; Mak TW; Yeung VT; Chan DC; Lam CW; Tsang LW; Chow CC; Cockram CS
    J Clin Pharmacol; 1998 Oct; 38(10):912-7. PubMed ID: 9807971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control.
    Mughal MA; Jan M; Maheri WM; Memon MY; Ali M
    J Pak Med Assoc; 2000 Nov; 50(11):381-6. PubMed ID: 11126815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
    Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
    Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
    Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO
    Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cholesterol lowering treatment on positive exercise tests in patients with hypercholesterolaemia and normal coronary angiograms.
    Mansur AP; Serrano CV; Nicolau JC; César LA; Ramires JA
    Heart; 1999 Dec; 82(6):689-93. PubMed ID: 10573494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study.
    Lindholm LH; Ekbom T; Dash C; Isacsson A; Scherstén B
    J Intern Med; 1996 Jul; 240(1):13-22. PubMed ID: 8708586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidaemia management after primary coronary artery bypass surgery: a survey of patients and general practitioners.
    Goldsmith I; Lip GY; Emsden K; Nugent A; Patel RL
    J Cardiovasc Risk; 1999 Aug; 6(4):263-7. PubMed ID: 10501279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
    Stewart MW; Dyer RG; Alberti KG; Laker MF
    Diabet Med; 1995 Mar; 12(3):250-7. PubMed ID: 7758262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.